Irbinitinib

  • CAT Number: I005570
  • CAS Number: 937263-43-9
  • Molecular Formula: C26H24N8O2
  • Molecular Weight: 480.52
  • Purity: ≥95%
Inquiry Now

Irbinitinib(CAT: I005570), also known as TP-0903, is an orally administered small molecule inhibitor of the receptor tyrosine kinase AXL. AXL plays a crucial role in the regulation of various cellular processes such as proliferation, migration, invasion, and survival. Overexpression of AXL has been associated with poor prognosis in various types of cancer. Irbinitinib has shown potent anti-tumor activity in preclinical studies and is being investigated in clinical trials for the treatment of solid tumors, including non-small cell lung cancer and triple-negative breast cancer.

Catalog Number I005570
CAS Number 937263-43-9
Molecular Formula

C26H24N8O2

Purity 95%
Target EGFR
Solubility 10 mM in DMSO
Storage 3 years -20C powder
Overview of Clinical Research

<span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>Irbinitinib is a&nbsp;<span style=”orphans: 2; widows: 2;”>ERBB 2 receptor antagonist. It has been granted for the orphan drug status in&nbsp;</span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Colorectal cancer and Breast cancer.</span></span></span></span>

IUPAC Name 6-N-(4,4-dimethyl-5H-1,3-oxazol-2-yl)-4-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine
InChI InChI=1S/C26H24N8O2/c1-16-10-17(5-7-22(16)36-19-8-9-34-23(12-19)28-15-30-34)31-24-20-11-18(4-6-21(20)27-14-29-24)32-25-33-26(2,3)13-35-25/h4-12,14-15H,13H2,1-3H3,(H,32,33)(H,27,29,31)
InChIKey SDEAXTCZPQIFQM-UHFFFAOYSA-N
SMILES CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC5=CC6=NC=NN6C=C5
Reference

<span style=”color:#000000;”><span style=”font-family:arial,helvetica,sans-serif;”><span style=”font-size:12px;”>1.<span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Moulder, Stacy L., et al. &quot;Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC).&quot;&nbsp;</span><i style=”font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;”>Clinical Cancer Research</i><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>&nbsp;23.14 (2017): 3529-3536.<br />
2.</span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Meric-Bernstam, Funda, et al. &quot;Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer.&quot;&nbsp;</span><i style=”font-family: Arial, sans-serif; font-size: 13px; font-variant-ligatures: normal; orphans: 2; widows: 2;”>Clinical Cancer Research</i><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>&nbsp;25.7 (2019): 2033-2041.<br />
3.</span><span style=”font-variant-ligatures: normal; orphans: 2; widows: 2;”>Lee, Patrice, et al. &quot;In vivo activity of ARRY-380, a potent, small Molecule inhibitor of ErbB2 in combination with trastuzumab, docetaxel or bevacizumab.&quot; (2009): 5104-5104.</span></span></span></span>

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!